Soligenix (NASDAQ: SNGX): Pioneering Breakthroughs in Rare Diseases
Jan. 16, 2024
Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryteTM or SGX301, a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.
Soligenix has also received positive and statistically significant results for its synthetic hypericin (SGX302) in a Phase 1/2 proof-of-concept study for the treatment of psoriasis. The company is now enrolling patients for the Phase 2a study in mild-to-moderate psoriasis. With an estimated global market potential of over $1 billion, SGX302 is another significant commercial opportunity in an area of unmet medical need. The Company is also developing SGX203 for the treatment of pediatric Crohn’s disease, with a pivotal Phase 3 study expected to commence subject to additional funding or partnership. To learn more visit, https://bit.ly/43TJ8ik
